SOUTH PLAINFIELD, N.J., Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC) ...
An ultra-rare enzyme deficiency that keeps infants from achieving proper muscle function among other developmental delays now has its first FDA-approved treatment. The new product, a gene therapy ...
On Thursday, the FDA granted accelerated approval to PTC Therapeutics, Inc.’s (NASDAQ:PTCT) gene therapy for AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly ...
When the Human Genome Project concluded 21 years ago, it opened the door for genetic testing and a promise for lifesaving screenings and personalized medicine. An innovation that serves as a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results